BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31617175)

  • 21. Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors.
    Melendez ME; Fraefel C; Epstein AL
    Methods Mol Biol; 2014; 1144():81-98. PubMed ID: 24671678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector.
    Taylor TJ; Diaz F; Colgrove RC; Bernard KA; DeLuca NA; Whelan SPJ; Knipe DM
    Virology; 2016 Sep; 496():186-193. PubMed ID: 27336950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes.
    Zaupa C; Revol-Guyot V; Epstein AL
    Hum Gene Ther; 2003 Jul; 14(11):1049-63. PubMed ID: 12885345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HSV-1 amplicon peptide display vector.
    Spear MA; Schuback D; Miyata K; Grandi P; Sun F; Yoo L; Nguyen A; Brandt CR; Breakefield XO
    J Virol Methods; 2003 Jan; 107(1):71-9. PubMed ID: 12445940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering HSV-1 Vectors for Gene Therapy.
    Goins WF; Huang S; Hall B; Marzulli M; Cohen JB; Glorioso JC
    Methods Mol Biol; 2020; 2060():73-90. PubMed ID: 31617173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration.
    Wang Y; Camp SM; Niwano M; Shen X; Bakowska JC; Breakefield XO; Allen PD
    J Virol; 2002 Jul; 76(14):7150-62. PubMed ID: 12072515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.
    Saeki Y; Fraefel C; Ichikawa T; Breakefield XO; Chiocca EA
    Mol Ther; 2001 Apr; 3(4):591-601. PubMed ID: 11319922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
    Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
    J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein.
    Rota RP; Palacios CA; Temprana CF; Argüelles MH; Mandile MG; Mattion N; Laimbacher AS; Fraefel C; Castello AA; Glikmann G
    J Virol Methods; 2018 Jun; 256():24-31. PubMed ID: 29496429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HSV-1-based amplicon particles are able to transduce cells of feline origin with genes encoding biologically functional feline IL-10 or IL-6.
    Vögtlin A; Fraefel C; Kocherhans R; Leutenegger CM; Frei K; Fontana A; Ackermann M
    Vet Microbiol; 2002 Apr; 86(1-2):103-13. PubMed ID: 11888694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons.
    Müller L; Saydam O; Saeki Y; Heid I; Fraefel C
    J Virol Methods; 2005 Jan; 123(1):65-72. PubMed ID: 15582700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors.
    Pechan PA; Fotaki M; Thompson RL; Dunn R; Chase M; Chiocca EA; Breakefield XO
    Hum Gene Ther; 1996 Oct; 7(16):2003-13. PubMed ID: 8930661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of high-titer defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells.
    Lim F; Hartley D; Starr P; Lang P; Song S; Yu L; Wang Y; Geller AI
    Biotechniques; 1996 Mar; 20(3):460-9. PubMed ID: 8679207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration.
    Sia KC; Wang GY; Ho IA; Khor HY; Miao L; Hui KM; Lam PY
    J Virol Methods; 2007 Feb; 139(2):166-74. PubMed ID: 17074404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge.
    Gorantla S; Santos K; Meyer V; Dewhurst S; Bowers WJ; Federoff HJ; Gendelman HE; Poluektova L
    J Virol; 2005 Feb; 79(4):2124-32. PubMed ID: 15681415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of high-titer defective HSV-1 vectors.
    Neve RL; Lim F
    Curr Protoc Neurosci; 2013 Jan; Chapter 4():Unit 4.13. PubMed ID: 23315945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.